Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tisotumab vedotin

(ty-SOH-too-mab veh-DOH-tin)
A drug used to treat adults with cervical cancer that has come back or has spread. It is used in patients whose cancer got worse during or after chemotherapy. It is also being studied in the treatment of other types of cancer. Tisotumab vedotin contains a monoclonal antibody that binds to a protein called tissue factor, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Tisotumab vedotin may also prevent the growth of new blood vessels that tumors need to grow. It is a type of antibody-drug conjugate and a type of antiangiogenesis agent. Also called Tivdak.
More Information
Search NCI's Dictionary of Cancer Terms